Compare · AMGN vs AURA
AMGN vs AURA
Side-by-side comparison of Amgen Inc. (AMGN) and Aura Biosciences Inc. (AURA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and AURA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $236.86B, about 307.4x AURA ($770.5M).
- Over the past year, AMGN is up 52.8% and AURA is up 18.0% - AMGN leads by 34.8 points.
- AURA has been more active in the news (15 items in the past 4 weeks vs 7 for AMGN).
- AMGN has more recent analyst coverage (25 ratings vs 11 for AURA).
- Company
- Amgen Inc.
- Aura Biosciences Inc.
- Price
- $438.13+1.95%
- $7.43+3.34%
- Market cap
- $236.86B
- $770.5M
- 1M return
- +15.64%
- +5.69%
- 1Y return
- +52.79%
- +18.02%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2021
- News (4w)
- 7
- 15
- Recent ratings
- 25
- 11
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Aura Biosciences Inc.
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform to treat tumors of high unmet need in ocular and urologic oncology. Its AU-011, a VDC candidate, is being developed for the first line treatment of primary choroidal melanoma, a rare disease with no drugs approved. The company also develops AU-011 in additional ocular oncology indications, including choroidal metastases. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Latest AMGN
- AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
- TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS
- SVP, Business Development Khosla Rachna exercised 1,252 shares at a strike of $162.60 and sold $1,346,499 worth of shares (3,252 units at $414.05), decreasing direct ownership by 24% to 6,404 units (SEC Form 4) to satisfy tax liability
- VP, Finance & CAO Busch Matthew C. was granted 730 shares, increasing direct ownership by 17% to 5,080 units (SEC Form 4)
- Director Ishrak Omar was granted 85 shares, increasing direct ownership by 1% to 7,486 units (SEC Form 4)
- Director Holley Charles M was granted 103 shares, increasing direct ownership by 0.80% to 12,990 units (SEC Form 4)
- Director Drake Michael V was granted 64 shares, increasing direct ownership by 1% to 5,876 units (SEC Form 4)
- SVP, Human Resources Miller Derek exercised 3,890 shares at a strike of $169.56 and sold $1,565,898 worth of shares (3,890 units at $402.54) (SEC Form 4) (tax liability)
- SVP & CCO Grygiel Nancy A. exercised 2,970 shares at a strike of $177.41 and sold $1,194,415 worth of shares (2,970 units at $402.16) (SEC Form 4) (for withholding tax)
- Truist reiterated coverage on Amgen with a new price target
Latest AURA
- Chief People Officer Person Julie was granted 107,611 shares (SEC Form 4)
- Chief Reg. & Quality Officer Kratz Erica was granted 100,885 shares (SEC Form 4)
- Chief Medical Officer Hopkins Janet Jill was granted 58,850 shares, increasing direct ownership by 18% to 380,190 units (SEC Form 4)
- SVP, Finance & PAO Elazzouzi Amy was granted 23,540 shares, increasing direct ownership by 20% to 143,600 units (SEC Form 4)
- Chief Operating Officer Abu-Absi Susan was granted 134,513 shares (SEC Form 4)
- SEC Form S-8 filed by Aura Biosciences Inc.
- Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- SEC Form EFFECT filed by Aura Biosciences Inc.
- SEC Form 3 filed by new insider Person Julie
- SEC Form 3 filed by new insider Kratz Erica